Breast cancer is not a single disease leading to abnormal cell division in breast tissues.
In the United States, it is estimated that more than 40,000 women will die from breast cancer in 2017.
According to DelveInsight’s estimates, the total Breast cancer incident population in the 7MM was found to be 626,867 in 2017, which is expected to grow in the coming years.
Metastatic HER2-Positive Breast Cancer
Metastatic HER2-Positive Breast Cancer is cancer in which biopsy test of cancerous cells show positive status for a protein receptor called human epidermal growth factor receptor 2 (HER 2). The normal protein regulates the healthy division of breast cells.
Metastatic HER2-Positive Breast cancer symptoms
Irritation or itching breasts, change in the colour of the breast, abnormal increase in the size of the breast or change in the shape in a short duration of time, changes in the texture of the breast, thickening or formation of lump, or peeling off the skin are some of the common Breast cancer symptoms.
Diagnosis of Metastatic HER2-Positive Breast Cancer
The HER 2 + Breast cancer diagnosis depends on several tests such as as the IHC test, the FISH test, the SPOT-Light HER2 CISH, and the Inform HER2 Dual ISH tests. These tests use antibodies or DNA to stain the cancer cells.
What is the Metastatic HER2-Positive Breast Cancer prevalence?
It is expected that approximately 12 per cent of women in the United States will develop invasive breast cancer at some point in their life.
Surprisingly, even men can develop HER2-positive breast cancer. However, Studies reveal that younger women are more prone to it.
Around 20% of all the cancers are accounted for Metastatic HER2-Positive Breast Cancer.
According to the American Cancer Society, about 17% of breast cancers overproduce the growth-promoting protein HER2.
Metastatic HER2-Positive Breast Cancer Therapy landscape
The Metastatic HER-2 Positive Breast Cancer market comprises a variety of treatment optionst, which is mainly categorized into pharmacological and non-pharmacological therapies.
Although the first-line treatment of metastatic breast cancer is mainly dependent on the receptor status, both estrogen and progesterone receptor status and HER2 receptor status should be tested.
If the tumour represents both HER2-positive and estrogen receptor-positive then initial treatment may include hormonal therapy or a HER2-targeted therapy or both. In hormonal therapy, Tamoxifen (AstraZeneca Pharmaceuticals) is a drug that blocks estrogen from binding to breast cancer cells. This agent is used for both premenopausal and postmenopausal women.
Trastuzumab (Herceptin), Pertuzumab (Perjeta), Ado-trastuzumab emtansine (Kadcyla), and Neratinib (Nerlynx) are some of the existing
Metastatic HER2-Positive Breast Cancer drugs that target HER2 protein.
Metastatic HER2-Positive Breast Cancer Pipeline
Neratinib (Puma Biotechnology), Tucatinib (Seattle Genetics), Pyrotinib (Jiangsu HengRui Medicine), HD201 (Prestige Biopharma Pte Ltd), EG12014 (EirGenix, Inc.) are the Metastatic HER2-Positive Breast Cancer upcoming therapies that are anticipated to impact the market significantly.
Metastatic HER2-Positive Breast Cancer Companies
Key players, such as MacroGenics, Puma Biotechnology, Seattle Genetics, Jiangsu HengRui Medicine, Prestige Biopharma Pte Ltd, EirGenix, Inc., and others are involved in developing therapies for Metastatic HER-2 Positive Breast Cancer.